2nd Cardiology Department, Attikon University Hospital, National & Kapodistrian University of Athens, 12461 Athens, Greece.
2nd Department of Dermatology and Venereology, Attikon University Hospital, Medical School, National & Kapodistrian University of Athens, 12461 Athens, Greece.
Nutrients. 2024 Aug 5;16(15):2572. doi: 10.3390/nu16152572.
Psoriasis predisposes to cardiovascular dysfunction. We investigated whether glycocalyx dietary supplement (GDS), which contains glycosaminoglycans and fucoidan, improves endothelial glycocalyx and arterial stiffness in psoriatic patients. Fifty participants with psoriasis under biological agents were randomly assigned to GDS (n = 25) or placebo (n = 25) for 4 months. We measured at baseline and at follow-up: (a) perfused boundary region (PBR) of the sublingual microvessels (range 4 to 25 μm), a marker of endothelium glycocalyx integrity; (b) carotid-femoral pulse wave velocity (PWV-Complior SP-ALAM) and augmentation index (AIx), markers of arterial stiffness and (c) psoriasis area and severity index (PASI) score. Both groups displayed a similar decrease in PASI at four months ( < 0.05), and no significant differences were found between groups ( > 0.05). Compared to the placebo, participants in the GDS showed a greater percentage reduction in PBR4-25 μm (-9.95% vs. -0.87%), PBR 4-9 μm (-6.50% vs. -0.82%), PBR10-19 μm (-5.12% vs. -1.60%), PBR 20-25 μm (-14.9% vs. -0.31%), PWV (-15.27% vs. -4.04%) and AIx (-35.57% vs. -21.85%) ( < 0.05). In the GDS group, the percentage reduction in PBR 4-25 μm was associated with the corresponding decrease in PWV (r = 0.411, = 0.015) and AΙx (r = 0.481, = 0.010) at follow-up. Four-month treatment with GDS improves glycocalyx integrity and arterial stiffness in patients with psoriasis. Clinical trial Identifier: NCT05184699.
银屑病易导致心血管功能障碍。我们研究了含有糖胺聚糖和岩藻聚糖的糖萼膳食补充剂（GDS）是否能改善银屑病患者的内皮糖萼和动脉僵硬。50 名接受生物制剂治疗的银屑病患者被随机分配到 GDS（n=25）或安慰剂（n=25）组，进行 4 个月的治疗。我们在基线和随访时测量了以下指标：（a）舌下微血管的灌注边界区（PBR）（范围 4 至 25μm），这是内皮糖萼完整性的标志物；（b）颈动脉-股动脉脉搏波速度（Complior SP-ALAM 型脉搏波速度仪）和增强指数（AIx），这是动脉僵硬的标志物；（c）银屑病面积和严重程度指数（PASI）评分。两组患者在四个月时 PASI 均有相似程度的下降（<0.05），且组间无显著差异（>0.05）。与安慰剂组相比，GDS 组的 PBR4-25μm（-9.95%比-0.87%）、PBR4-9μm（-6.50%比-0.82%）、PBR10-19μm（-5.12%比-1.60%）、PBR20-25μm（-14.9%比-0.31%）、PWV（-15.27%比-4.04%）和 AIx（-35.57%比-21.85%）的下降百分比更大（<0.05）。在 GDS 组中，PBR4-25μm 的下降百分比与随访时 PWV（r=0.411，p=0.015）和 AIx（r=0.481，p=0.010）的相应下降呈正相关。GDS 治疗 4 个月可改善银屑病患者的糖萼完整性和动脉僵硬。临床试验注册号：NCT05184699。
